ID   PPARA_HUMAN             Reviewed;         468 AA.
AC   Q07869; B0G0X3; Q16241; Q6I9S0; Q92486; Q92689; Q9Y3N1;
DT   01-OCT-1994, integrated into UniProtKB/Swiss-Prot.
DT   15-JUL-1998, sequence version 2.
DT   10-MAY-2017, entry version 203.
DE   RecName: Full=Peroxisome proliferator-activated receptor alpha;
DE            Short=PPAR-alpha;
DE   AltName: Full=Nuclear receptor subfamily 1 group C member 1;
GN   Name=PPARA; Synonyms=NR1C1, PPAR;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), FUNCTION, AND VARIANT VAL-268.
RC   TISSUE=Liver;
RX   PubMed=7684926; DOI=10.1021/bi00072a015;
RA   Sher T., Yi H.F., McBride O.W., Gonzales F.J.;
RT   "cDNA cloning, chromosomal mapping, and functional characterization of
RT   the human peroxisome proliferator activated receptor.";
RL   Biochemistry 32:5598-5604(1993).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND TISSUE SPECIFICITY.
RC   TISSUE=Liver;
RX   PubMed=7981125; DOI=10.1016/0960-0760(94)90089-2;
RA   Mukherjee R., Jow L., Noonan D., McDonnell D.P.;
RT   "Human and rat peroxisome proliferator activated receptors (PPARs)
RT   demonstrate similar tissue distribution but different responsiveness
RT   to PPAR activators.";
RL   J. Steroid Biochem. Mol. Biol. 51:157-166(1994).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND TISSUE SPECIFICITY.
RX   PubMed=8993548; DOI=10.1111/j.1749-6632.1996.tb18620.x;
RA   Tugwood J.D., Aldridge T.C., Lambe K.G., Macdonald N., Woodyatt N.J.;
RT   "Peroxisome proliferator-activated receptors: structures and
RT   function.";
RL   Ann. N. Y. Acad. Sci. 804:252-265(1996).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RX   PubMed=18619963; DOI=10.1016/j.febslet.2008.07.003;
RA   Kobayashi T., Kodani Y., Nozawa A., Endo Y., Sawasaki T.;
RT   "DNA-binding profiling of human hormone nuclear receptors via
RT   fluorescence correlation spectroscopy in a cell-free system.";
RL   FEBS Lett. 582:2737-2744(2008).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RX   PubMed=19263263; DOI=10.1080/08923970902785246;
RA   Cho M.-C., Lee S., Choi H.S., Yang Y., Tae Hong J., Kim S.J.,
RA   Yoon D.-Y.;
RT   "Optimization of an enzyme-linked immunosorbent assay to screen ligand
RT   of Peroxisome proliferator-activated receptor alpha.";
RL   Immunopharmacol. Immunotoxicol. 31:459-467(2009).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2).
RA   Jiang Y., Xie Z., Liu H., Liu M., Liu F.;
RT   "A novel alternatively spliced peroxisome proliferator-activated
RT   receptor alpha.";
RL   Submitted (JAN-2008) to the EMBL/GenBank/DDBJ databases.
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RX   PubMed=15461802; DOI=10.1186/gb-2004-5-10-r84;
RA   Collins J.E., Wright C.L., Edwards C.A., Davis M.P., Grinham J.A.,
RA   Cole C.G., Goward M.E., Aguado B., Mallya M., Mokrab Y., Huckle E.J.,
RA   Beare D.M., Dunham I.;
RT   "A genome annotation-driven approach to cloning the human ORFeome.";
RL   Genome Biol. 5:R84.1-R84.11(2004).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Brain;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [9]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RA   Ebert L., Schick M., Neubert P., Schatten R., Henze S., Korn B.;
RT   "Cloning of human full open reading frames in Gateway(TM) system entry
RT   vector (pDONR201).";
RL   Submitted (JUN-2004) to the EMBL/GenBank/DDBJ databases.
RN   [10]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANT VAL-162.
RG   SeattleSNPs variation discovery resource;
RL   Submitted (DEC-2002) to the EMBL/GenBank/DDBJ databases.
RN   [11]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=10591208; DOI=10.1038/990031;
RA   Dunham I., Hunt A.R., Collins J.E., Bruskiewich R., Beare D.M.,
RA   Clamp M., Smink L.J., Ainscough R., Almeida J.P., Babbage A.K.,
RA   Bagguley C., Bailey J., Barlow K.F., Bates K.N., Beasley O.P.,
RA   Bird C.P., Blakey S.E., Bridgeman A.M., Buck D., Burgess J.,
RA   Burrill W.D., Burton J., Carder C., Carter N.P., Chen Y., Clark G.,
RA   Clegg S.M., Cobley V.E., Cole C.G., Collier R.E., Connor R.,
RA   Conroy D., Corby N.R., Coville G.J., Cox A.V., Davis J., Dawson E.,
RA   Dhami P.D., Dockree C., Dodsworth S.J., Durbin R.M., Ellington A.G.,
RA   Evans K.L., Fey J.M., Fleming K., French L., Garner A.A.,
RA   Gilbert J.G.R., Goward M.E., Grafham D.V., Griffiths M.N.D., Hall C.,
RA   Hall R.E., Hall-Tamlyn G., Heathcott R.W., Ho S., Holmes S.,
RA   Hunt S.E., Jones M.C., Kershaw J., Kimberley A.M., King A.,
RA   Laird G.K., Langford C.F., Leversha M.A., Lloyd C., Lloyd D.M.,
RA   Martyn I.D., Mashreghi-Mohammadi M., Matthews L.H., Mccann O.T.,
RA   Mcclay J., Mclaren S., McMurray A.A., Milne S.A., Mortimore B.J.,
RA   Odell C.N., Pavitt R., Pearce A.V., Pearson D., Phillimore B.J.C.T.,
RA   Phillips S.H., Plumb R.W., Ramsay H., Ramsey Y., Rogers L., Ross M.T.,
RA   Scott C.E., Sehra H.K., Skuce C.D., Smalley S., Smith M.L.,
RA   Soderlund C., Spragon L., Steward C.A., Sulston J.E., Swann R.M.,
RA   Vaudin M., Wall M., Wallis J.M., Whiteley M.N., Willey D.L.,
RA   Williams L., Williams S.A., Williamson H., Wilmer T.E., Wilming L.,
RA   Wright C.L., Hubbard T., Bentley D.R., Beck S., Rogers J., Shimizu N.,
RA   Minoshima S., Kawasaki K., Sasaki T., Asakawa S., Kudoh J.,
RA   Shintani A., Shibuya K., Yoshizaki Y., Aoki N., Mitsuyama S.,
RA   Roe B.A., Chen F., Chu L., Crabtree J., Deschamps S., Do A., Do T.,
RA   Dorman A., Fang F., Fu Y., Hu P., Hua A., Kenton S., Lai H., Lao H.I.,
RA   Lewis J., Lewis S., Lin S.-P., Loh P., Malaj E., Nguyen T., Pan H.,
RA   Phan S., Qi S., Qian Y., Ray L., Ren Q., Shaull S., Sloan D., Song L.,
RA   Wang Q., Wang Y., Wang Z., White J., Willingham D., Wu H., Yao Z.,
RA   Zhan M., Zhang G., Chissoe S., Murray J., Miller N., Minx P.,
RA   Fulton R., Johnson D., Bemis G., Bentley D., Bradshaw H., Bourne S.,
RA   Cordes M., Du Z., Fulton L., Goela D., Graves T., Hawkins J.,
RA   Hinds K., Kemp K., Latreille P., Layman D., Ozersky P., Rohlfing T.,
RA   Scheet P., Walker C., Wamsley A., Wohldmann P., Pepin K., Nelson J.,
RA   Korf I., Bedell J.A., Hillier L.W., Mardis E., Waterston R.,
RA   Wilson R., Emanuel B.S., Shaikh T., Kurahashi H., Saitta S.,
RA   Budarf M.L., McDermid H.E., Johnson A., Wong A.C.C., Morrow B.E.,
RA   Edelmann L., Kim U.J., Shizuya H., Simon M.I., Dumanski J.P.,
RA   Peyrard M., Kedra D., Seroussi E., Fransson I., Tapia I., Bruder C.E.,
RA   O'Brien K.P., Wilkinson P., Bodenteich A., Hartman K., Hu X.,
RA   Khan A.S., Lane L., Tilahun Y., Wright H.;
RT   "The DNA sequence of human chromosome 22.";
RL   Nature 402:489-495(1999).
RN   [12]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [13]
RP   HETERODIMERIZATION WITH RXRA, FUNCTION, AND MUTAGENESIS OF CYS-122;
RP   LEU-422 AND LEU-433.
RX   PubMed=7629123; DOI=10.1074/jbc.270.30.18117;
RA   Juge-Aubry C.E., Gorla-Bajszczak A., Pernin A., Lemberger T.,
RA   Wahli W., Burger A.G., Meier C.A.;
RT   "Peroxisome proliferator-activated receptor mediates cross-talk with
RT   thyroid hormone receptor by competition for retinoid X receptor.
RT   Possible role of a leucine zipper-like heptad repeat.";
RL   J. Biol. Chem. 270:18117-18122(1995).
RN   [14]
RP   INTERACTION WITH NCOA3.
RX   PubMed=9238002; DOI=10.1073/pnas.94.16.8479;
RA   Li H., Gomes P.J., Chen J.D.;
RT   "RAC3, a steroid/nuclear receptor-associated coactivator that is
RT   related to SRC-1 and TIF2.";
RL   Proc. Natl. Acad. Sci. U.S.A. 94:8479-8484(1997).
RN   [15]
RP   FUNCTION.
RX   PubMed=9556573; DOI=10.1074/jbc.273.18.10948;
RA   Yan Z.H., Karam W.G., Staudinger J.L., Medvedev A., Ghanayem B.I.,
RA   Jetten A.M.;
RT   "Regulation of peroxisome proliferator-activated receptor alpha-
RT   induced transactivation by the nuclear orphan receptor TAK1/TR4.";
RL   J. Biol. Chem. 273:10948-10957(1998).
RN   [16]
RP   HETERODIMERIZATION WITH RXRA, FUNCTION, AND MUTAGENESIS OF ASP-304;
RP   LEU-370; LEU-391 AND ALA-431.
RX   PubMed=10195690; DOI=10.1016/S0303-7207(98)00217-2;
RA   Gorla-Bajszczak A., Juge-Aubry C., Pernin A., Burger A.G., Meier C.A.;
RT   "Conserved amino acids in the ligand-binding and tau(i) domains of the
RT   peroxisome proliferator-activated receptor alpha are necessary for
RT   heterodimerization with RXR.";
RL   Mol. Cell. Endocrinol. 147:37-47(1999).
RN   [17]
RP   INTERACTION WITH NCOA6.
RX   PubMed=10681503; DOI=10.1074/jbc.275.8.5308;
RA   Caira F., Antonson P., Pelto-Huikko M., Treuter E., Gustafsson J.-A.;
RT   "Cloning and characterization of RAP250, a nuclear receptor
RT   coactivator.";
RL   J. Biol. Chem. 275:5308-5317(2000).
RN   [18]
RP   HETERODIMERIZATION WITH RXRA.
RX   PubMed=11915042; DOI=10.1053/jhep.2002.32470;
RA   Tsutsumi T., Suzuki T., Shimoike T., Suzuki R., Moriya K.,
RA   Shintani Y., Fujie H., Matsuura Y., Koike K., Miyamura T.;
RT   "Interaction of hepatitis C virus core protein with retinoid X
RT   receptor alpha modulates its transcriptional activity.";
RL   Hepatology 35:937-946(2002).
RN   [19]
RP   IDENTIFICATION AS RECEPTOR FOR OLEYLETHANOLAMIDE.
RX   PubMed=12955147; DOI=10.1038/nature01921;
RA   Fu J., Gaetani S., Oveisi F., Lo Verme J., Serrano A.,
RA   Rodriguez De Fonseca F., Rosengarth A., Luecke H., Di Giacomo B.,
RA   Tarzia G., Piomelli D.;
RT   "Oleylethanolamide regulates feeding and body weight through
RT   activation of the nuclear receptor PPAR-alpha.";
RL   Nature 425:90-93(2003).
RN   [20]
RP   INTERACTION WITH ASXL1 AND ASXL2.
RX   PubMed=21047783; DOI=10.1074/jbc.M110.177816;
RA   Park U.H., Yoon S.K., Park T., Kim E.J., Um S.J.;
RT   "Additional sex comb-like (ASXL) proteins 1 and 2 play opposite roles
RT   in adipogenesis via reciprocal regulation of peroxisome proliferator-
RT   activated receptor {gamma}.";
RL   J. Biol. Chem. 286:1354-1363(2011).
RN   [21]
RP   INTERACTION WITH SIRT1, AND FUNCTION.
RX   PubMed=24043310; DOI=10.1128/MCB.00087-13;
RA   Laurent G., de Boer V.C., Finley L.W., Sweeney M., Lu H., Schug T.T.,
RA   Cen Y., Jeong S.M., Li X., Sauve A.A., Haigis M.C.;
RT   "SIRT4 represses peroxisome proliferator-activated receptor alpha
RT   activity to suppress hepatic fat oxidation.";
RL   Mol. Cell. Biol. 33:4552-4561(2013).
RN   [22]
RP   X-RAY CRYSTALLOGRAPHY (2.5 ANGSTROMS) OF 192-468 IN COMPLEX WITH
RP   SYNTHETIC AGONIST.
RX   PubMed=11698662; DOI=10.1073/pnas.241410198;
RA   Xu H.E., Lambert M.H., Montana V.G., Plunket K.D., Moore L.B.,
RA   Collins J.L., Oplinger J.A., Kliewer S.A., Gampe R.T. Jr., McKee D.D.,
RA   Moore J.T., Willson T.M.;
RT   "Structural determinants of ligand binding selectivity between the
RT   peroxisome proliferator-activated receptors.";
RL   Proc. Natl. Acad. Sci. U.S.A. 98:13919-13924(2001).
RN   [23]
RP   X-RAY CRYSTALLOGRAPHY (2.24 ANGSTROMS) OF 196-468 IN COMPLEX WITH
RP   SYNTHETIC AGONIST.
RX   PubMed=11587644; DOI=10.1016/S0969-2126(01)00634-7;
RA   Cronet P., Petersen J.F.W., Folmer R., Blomberg N., Sjoeblom K.,
RA   Karlsson U., Lindstedt E.-L., Bamberg K.;
RT   "Structure of the PPARalpha and -gamma ligand binding domain in
RT   complex with AZ 242; ligand selectivity and agonist activation in the
RT   PPAR family.";
RL   Structure 9:699-706(2001).
RN   [24]
RP   X-RAY CRYSTALLOGRAPHY (2.5 ANGSTROMS) OF 200-468 IN COMPLEX WITH
RP   SYNTHETIC AGONIST.
RX   PubMed=11845213; DOI=10.1038/415813a;
RA   Xu H.E., Stanley T.B., Montana V.G., Lambert M.H., Shearer B.G.,
RA   Cobb J.E., McKee D.D., Galardi C.M., Plunket K.D., Nolte R.T.,
RA   Parks D.J., Moore J.T., Kliewer S.A., Willson T.M., Stimmel J.B.;
RT   "Structural basis for antagonist-mediated recruitment of nuclear co-
RT   repressors by PPARalpha.";
RL   Nature 415:813-817(2002).
RN   [25]
RP   X-RAY CRYSTALLOGRAPHY (2.3 ANGSTROMS) OF 199-468 IN COMPLEX WITH
RP   SYNTHETIC AGONIST.
RX   PubMed=17157019; DOI=10.1016/j.bmcl.2006.11.050;
RA   Oon Han H., Kim S.H., Kim K.-H., Hur G.-C., Joo Yim H., Chung H.-K.,
RA   Ho Woo S., Dong Koo K., Lee C.-S., Sung Koh J., Kim G.T.;
RT   "Design and synthesis of oxime ethers of alpha-acyl-beta-
RT   phenylpropanoic acids as PPAR dual agonists.";
RL   Bioorg. Med. Chem. Lett. 17:937-941(2007).
RN   [26]
RP   X-RAY CRYSTALLOGRAPHY (1.79 ANGSTROMS) OF 202-468 IN COMPLEX WITH
RP   SYNTHETIC AGONIST.
RX   PubMed=17243659; DOI=10.1021/jm058056x;
RA   Sierra M.L., Beneton V., Boullay A.-B., Boyer T., Brewster A.G.,
RA   Donche F., Forest M.-C., Fouchet M.-H., Gellibert F.J., Grillot D.A.,
RA   Lambert M.H., Laroze A., Le Grumelec C., Linget J.M., Montana V.G.,
RA   Nguyen V.-L., Nicodeme E., Patel V., Penfornis A., Pineau O.,
RA   Pohin D., Potvain F., Poulain G., Ruault C.B., Saunders M., Toum J.,
RA   Xu H.E., Xu R.X., Pianetti P.M.;
RT   "Substituted 2-[(4-aminomethyl)phenoxy]-2-methylpropionic acid
RT   PPARalpha agonists. 1. Discovery of a novel series of potent HDLc
RT   raising agents.";
RL   J. Med. Chem. 50:685-695(2007).
RN   [27]
RP   X-RAY CRYSTALLOGRAPHY (2.01 ANGSTROMS) OF 200-468 IN COMPLEX WITH THE
RP   SYNTHETIC AGONIST TIPP-703.
RX   PubMed=19622862; DOI=10.1107/S0907444909015935;
RA   Oyama T., Toyota K., Waku T., Hirakawa Y., Nagasawa N., Kasuga J.I.,
RA   Hashimoto Y., Miyachi H., Morikawa K.;
RT   "Adaptability and selectivity of human peroxisome proliferator-
RT   activated receptor (PPAR) pan agonists revealed from crystal
RT   structures.";
RL   Acta Crystallogr. D 65:786-795(2009).
RN   [28]
RP   X-RAY CRYSTALLOGRAPHY (2.2 ANGSTROMS) OF 199-468 IN COMPLEX WITH
RP   ALEGLITAZAR.
RX   PubMed=19349176; DOI=10.1016/j.bmcl.2009.03.036;
RA   Benardeau A., Benz J., Binggeli A., Blum D., Boehringer M.,
RA   Grether U., Hilpert H., Kuhn B., Maerki H.P., Meyer M., Puentener K.,
RA   Raab S., Ruf A., Schlatter D., Mohr P.;
RT   "Aleglitazar, a new, potent, and balanced dual PPARalpha/gamma agonist
RT   for the treatment of type II diabetes.";
RL   Bioorg. Med. Chem. Lett. 19:2468-2473(2009).
RN   [29]
RP   X-RAY CRYSTALLOGRAPHY (2.5 ANGSTROMS) OF 199-468 IN COMPLEX WITH
RP   INDEGLITAZAR.
RX   PubMed=19116277; DOI=10.1073/pnas.0811325106;
RA   Artis D.R., Lin J.J., Zhang C., Wang W., Mehra U., Perreault M.,
RA   Erbe D., Krupka H.I., England B.P., Arnold J., Plotnikov A.N.,
RA   Marimuthu A., Nguyen H., Will S., Signaevsky M., Kral J., Cantwell J.,
RA   Settachatgull C., Yan D.S., Fong D., Oh A., Shi S., Womack P.,
RA   Powell B., Habets G., West B.L., Zhang K.Y.J., Milburn M.V.,
RA   Vlasuk G.P., Hirth K.P., Nolop K., Bollag G., Ibrahim P.N.,
RA   Tobin J.F.;
RT   "Scaffold-based discovery of indeglitazar, a PPAR pan-active anti-
RT   diabetic agent.";
RL   Proc. Natl. Acad. Sci. U.S.A. 106:262-267(2009).
CC   -!- FUNCTION: Ligand-activated transcription factor. Key regulator of
CC       lipid metabolism. Activated by the endogenous ligand 1-palmitoyl-
CC       2-oleoyl-sn-glycerol-3-phosphocholine (16:0/18:1-GPC). Activated
CC       by oleylethanolamide, a naturally occurring lipid that regulates
CC       satiety. Receptor for peroxisome proliferators such as
CC       hypolipidemic drugs and fatty acids. Regulates the peroxisomal
CC       beta-oxidation pathway of fatty acids. Functions as transcription
CC       activator for the ACOX1 and P450 genes. Transactivation activity
CC       requires heterodimerization with RXRA and is antagonized by NR2C2.
CC       May be required for the propagation of clock information to
CC       metabolic pathways regulated by PER2.
CC       {ECO:0000269|PubMed:10195690, ECO:0000269|PubMed:24043310,
CC       ECO:0000269|PubMed:7629123, ECO:0000269|PubMed:7684926,
CC       ECO:0000269|PubMed:9556573}.
CC   -!- SUBUNIT: Heterodimer; with RXRA. This heterodimerization is
CC       required for DNA binding and transactivation activity. Interacts
CC       with NCOA3 coactivator. Interacts with CITED2; the interaction
CC       stimulates its transcriptional activity. Also interacts with
CC       PPARBP in vitro. Interacts with AKAP13, LPIN1, PRDM16 and
CC       coactivator NCOA6. Interacts with ASXL1 and ASXL2. Interacts with
CC       PER2. Interacts with SIRT1; the interaction seems to be modulated
CC       by NAD(+) levels (PubMed:24043310). {ECO:0000250|UniProtKB:P23204,
CC       ECO:0000250|UniProtKB:P37230, ECO:0000269|PubMed:10681503,
CC       ECO:0000269|PubMed:11587644, ECO:0000269|PubMed:11698662,
CC       ECO:0000269|PubMed:11845213, ECO:0000269|PubMed:17157019,
CC       ECO:0000269|PubMed:17243659, ECO:0000269|PubMed:19116277,
CC       ECO:0000269|PubMed:19349176, ECO:0000269|PubMed:19622862,
CC       ECO:0000269|PubMed:21047783, ECO:0000269|PubMed:24043310,
CC       ECO:0000269|PubMed:9238002}.
CC   -!- INTERACTION:
CC       Q3L8U1-3:CHD9; NbExp=2; IntAct=EBI-78615, EBI-960730;
CC       P62993:GRB2; NbExp=3; IntAct=EBI-78615, EBI-401755;
CC       O75376:NCOR1; NbExp=3; IntAct=EBI-78615, EBI-347233;
CC   -!- SUBCELLULAR LOCATION: Nucleus.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=Q07869-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=Q07869-2; Sequence=VSP_047571, VSP_047572;
CC   -!- TISSUE SPECIFICITY: Skeletal muscle, liver, heart and kidney.
CC       {ECO:0000269|PubMed:7981125, ECO:0000269|PubMed:8993548}.
CC   -!- SIMILARITY: Belongs to the nuclear hormone receptor family. NR1
CC       subfamily. {ECO:0000305}.
CC   -!- WEB RESOURCE: Name=Wikipedia; Note=Peroxisome proliferator-
CC       activated receptor entry;
CC       URL="https://en.wikipedia.org/wiki/Peroxisome_proliferator-activated_receptor";
CC   -!- WEB RESOURCE: Name=SeattleSNPs;
CC       URL="http://pga.gs.washington.edu/data/ppara/";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; L02932; AAA36468.1; -; mRNA.
DR   EMBL; S74349; AAB32649.1; -; mRNA.
DR   EMBL; Y07619; CAA68898.1; -; mRNA.
DR   EMBL; AB307690; BAH02281.1; -; mRNA.
DR   EMBL; EU650667; ACD12656.1; -; mRNA.
DR   EMBL; EU395809; ABY73535.1; -; mRNA.
DR   EMBL; CR456547; CAG30433.1; -; mRNA.
DR   EMBL; AK289821; BAF82510.1; -; mRNA.
DR   EMBL; CR457435; CAG33716.1; -; mRNA.
DR   EMBL; AY206718; AAO13489.1; -; Genomic_DNA.
DR   EMBL; AL049856; CAI22450.1; -; Genomic_DNA.
DR   EMBL; AL078611; CAI22450.1; JOINED; Genomic_DNA.
DR   EMBL; Z94161; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471138; EAW73402.1; -; Genomic_DNA.
DR   CCDS; CCDS33669.1; -. [Q07869-1]
DR   PIR; A49289; A49289.
DR   PIR; I56603; I56603.
DR   RefSeq; NP_001001928.1; NM_001001928.2. [Q07869-1]
DR   RefSeq; NP_005027.2; NM_005036.4. [Q07869-1]
DR   RefSeq; XP_005261712.1; XM_005261655.3. [Q07869-1]
DR   RefSeq; XP_005261713.1; XM_005261656.3. [Q07869-1]
DR   RefSeq; XP_006724332.1; XM_006724269.3. [Q07869-1]
DR   RefSeq; XP_006724333.1; XM_006724270.3. [Q07869-1]
DR   RefSeq; XP_011528541.1; XM_011530239.2. [Q07869-1]
DR   RefSeq; XP_011528542.1; XM_011530240.2. [Q07869-1]
DR   RefSeq; XP_011528543.1; XM_011530241.2. [Q07869-1]
DR   RefSeq; XP_011528544.1; XM_011530242.2. [Q07869-1]
DR   RefSeq; XP_011528545.1; XM_011530243.2. [Q07869-1]
DR   UniGene; Hs.103110; -.
DR   UniGene; Hs.710044; -.
DR   PDB; 1I7G; X-ray; 2.20 A; A=196-468.
DR   PDB; 1K7L; X-ray; 2.50 A; A/C/E/G=192-468.
DR   PDB; 1KKQ; X-ray; 3.00 A; A/B/C/D=200-468.
DR   PDB; 2NPA; X-ray; 2.30 A; A/C=199-468.
DR   PDB; 2P54; X-ray; 1.79 A; A=202-468.
DR   PDB; 2REW; X-ray; 2.35 A; A=196-468.
DR   PDB; 2ZNN; X-ray; 2.01 A; A=200-468.
DR   PDB; 3ET1; X-ray; 2.50 A; A/B=199-468.
DR   PDB; 3FEI; X-ray; 2.40 A; A=202-468.
DR   PDB; 3G8I; X-ray; 2.20 A; A=199-468.
DR   PDB; 3KDT; X-ray; 2.70 A; A/B=196-468.
DR   PDB; 3KDU; X-ray; 2.07 A; A/B=196-468.
DR   PDB; 3SP6; X-ray; 2.21 A; A=196-468.
DR   PDB; 3VI8; X-ray; 1.75 A; A=200-468.
DR   PDB; 4BCR; X-ray; 2.50 A; A/B=195-468.
DR   PDB; 4CI4; X-ray; 2.30 A; A=195-468.
DR   PDB; 5AZT; X-ray; 3.45 A; A/B=201-468.
DR   PDB; 5HYK; X-ray; 1.83 A; A=200-468.
DR   PDBsum; 1I7G; -.
DR   PDBsum; 1K7L; -.
DR   PDBsum; 1KKQ; -.
DR   PDBsum; 2NPA; -.
DR   PDBsum; 2P54; -.
DR   PDBsum; 2REW; -.
DR   PDBsum; 2ZNN; -.
DR   PDBsum; 3ET1; -.
DR   PDBsum; 3FEI; -.
DR   PDBsum; 3G8I; -.
DR   PDBsum; 3KDT; -.
DR   PDBsum; 3KDU; -.
DR   PDBsum; 3SP6; -.
DR   PDBsum; 3VI8; -.
DR   PDBsum; 4BCR; -.
DR   PDBsum; 4CI4; -.
DR   PDBsum; 5AZT; -.
DR   PDBsum; 5HYK; -.
DR   ProteinModelPortal; Q07869; -.
DR   SMR; Q07869; -.
DR   BioGrid; 111461; 43.
DR   DIP; DIP-241N; -.
DR   IntAct; Q07869; 18.
DR   MINT; MINT-232229; -.
DR   STRING; 9606.ENSP00000262735; -.
DR   BindingDB; Q07869; -.
DR   ChEMBL; CHEMBL239; -.
DR   DrugBank; DB07724; 3-{5-methoxy-1-[(4-methoxyphenyl)sulfonyl]-1H-indol-3-yl}propanoic acid.
DR   DrugBank; DB08915; Aleglitazar.
DR   DrugBank; DB01393; Bezafibrate.
DR   DrugBank; DB00636; Clofibrate.
DR   DrugBank; DB01039; Fenofibrate.
DR   DrugBank; DB01241; Gemfibrozil.
DR   DrugBank; DB05187; GFT505.
DR   DrugBank; DB00328; Indomethacin.
DR   DrugBank; DB01708; Prasterone.
DR   DrugBank; DB04971; Reglixane.
DR   GuidetoPHARMACOLOGY; 593; -.
DR   SwissLipids; SLP:000001644; -.
DR   iPTMnet; Q07869; -.
DR   PhosphoSitePlus; Q07869; -.
DR   BioMuta; PPARA; -.
DR   DMDM; 3041727; -.
DR   PaxDb; Q07869; -.
DR   PeptideAtlas; Q07869; -.
DR   PRIDE; Q07869; -.
DR   DNASU; 5465; -.
DR   Ensembl; ENST00000262735; ENSP00000262735; ENSG00000186951. [Q07869-1]
DR   Ensembl; ENST00000402126; ENSP00000385246; ENSG00000186951. [Q07869-1]
DR   Ensembl; ENST00000407236; ENSP00000385523; ENSG00000186951. [Q07869-1]
DR   GeneID; 5465; -.
DR   KEGG; hsa:5465; -.
DR   UCSC; uc003bgx.1; human. [Q07869-1]
DR   CTD; 5465; -.
DR   DisGeNET; 5465; -.
DR   GeneCards; PPARA; -.
DR   HGNC; HGNC:9232; PPARA.
DR   HPA; HPA058901; -.
DR   HPA; HPA067049; -.
DR   MIM; 170998; gene+phenotype.
DR   neXtProt; NX_Q07869; -.
DR   OpenTargets; ENSG00000186951; -.
DR   PharmGKB; PA280; -.
DR   eggNOG; KOG3575; Eukaryota.
DR   eggNOG; ENOG410XRZC; LUCA.
DR   GeneTree; ENSGT00870000136388; -.
DR   HOGENOM; HOG000261626; -.
DR   HOVERGEN; HBG106004; -.
DR   InParanoid; Q07869; -.
DR   KO; K07294; -.
DR   OMA; YGSGFIT; -.
DR   OrthoDB; EOG091G05U8; -.
DR   PhylomeDB; Q07869; -.
DR   TreeFam; TF316304; -.
DR   Reactome; R-HSA-1368082; RORA activates gene expression.
DR   Reactome; R-HSA-1368108; BMAL1:CLOCK,NPAS2 activates circadian gene expression.
DR   Reactome; R-HSA-1989781; PPARA activates gene expression.
DR   Reactome; R-HSA-2032785; YAP1- and WWTR1 (TAZ)-stimulated gene expression.
DR   Reactome; R-HSA-2151201; Transcriptional activation of mitochondrial biogenesis.
DR   Reactome; R-HSA-2426168; Activation of gene expression by SREBF (SREBP).
DR   Reactome; R-HSA-381340; Transcriptional regulation of white adipocyte differentiation.
DR   Reactome; R-HSA-383280; Nuclear Receptor transcription pathway.
DR   Reactome; R-HSA-400206; Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha).
DR   Reactome; R-HSA-400253; Circadian Clock.
DR   SignaLink; Q07869; -.
DR   SIGNOR; Q07869; -.
DR   ChiTaRS; PPARA; human.
DR   EvolutionaryTrace; Q07869; -.
DR   GeneWiki; Peroxisome_proliferator-activated_receptor_alpha; -.
DR   GenomeRNAi; 5465; -.
DR   PRO; PR:Q07869; -.
DR   Proteomes; UP000005640; Chromosome 22.
DR   Bgee; ENSG00000186951; -.
DR   CleanEx; HS_PPARA; -.
DR   ExpressionAtlas; Q07869; baseline and differential.
DR   Genevisible; Q07869; HS.
DR   GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR   GO; GO:0005634; C:nucleus; IDA:BHF-UCL.
DR   GO; GO:0003677; F:DNA binding; TAS:ProtInc.
DR   GO; GO:0008144; F:drug binding; IDA:UniProtKB.
DR   GO; GO:0008289; F:lipid binding; IDA:UniProtKB.
DR   GO; GO:0097371; F:MDM2/MDM4 family protein binding; IEA:Ensembl.
DR   GO; GO:0051525; F:NFAT protein binding; IEA:Ensembl.
DR   GO; GO:0019902; F:phosphatase binding; IEA:Ensembl.
DR   GO; GO:0032403; F:protein complex binding; IEA:Ensembl.
DR   GO; GO:0019904; F:protein domain specific binding; IEA:Ensembl.
DR   GO; GO:0000978; F:RNA polymerase II core promoter proximal region sequence-specific DNA binding; IDA:NTNU_SB.
DR   GO; GO:0001103; F:RNA polymerase II repressing transcription factor binding; IPI:BHF-UCL.
DR   GO; GO:0004879; F:RNA polymerase II transcription factor activity, ligand-activated sequence-specific DNA binding; IDA:UniProtKB.
DR   GO; GO:0043565; F:sequence-specific DNA binding; ISS:BHF-UCL.
DR   GO; GO:0003707; F:steroid hormone receptor activity; IDA:BHF-UCL.
DR   GO; GO:0001223; F:transcription coactivator binding; IEA:Ensembl.
DR   GO; GO:0003700; F:transcription factor activity, sequence-specific DNA binding; IDA:BHF-UCL.
DR   GO; GO:0008134; F:transcription factor binding; IPI:UniProtKB.
DR   GO; GO:0001077; F:transcriptional activator activity, RNA polymerase II core promoter proximal region sequence-specific binding; IDA:NTNU_SB.
DR   GO; GO:0001190; F:transcriptional activator activity, RNA polymerase II transcription factor binding; IEA:Ensembl.
DR   GO; GO:0001078; F:transcriptional repressor activity, RNA polymerase II core promoter proximal region sequence-specific binding; IDA:NTNU_SB.
DR   GO; GO:0031624; F:ubiquitin conjugating enzyme binding; IPI:BHF-UCL.
DR   GO; GO:0008270; F:zinc ion binding; IEA:InterPro.
DR   GO; GO:0035095; P:behavioral response to nicotine; IEA:Ensembl.
DR   GO; GO:0044255; P:cellular lipid metabolic process; TAS:Reactome.
DR   GO; GO:0032922; P:circadian regulation of gene expression; ISS:UniProtKB.
DR   GO; GO:0070166; P:enamel mineralization; IEA:Ensembl.
DR   GO; GO:0008544; P:epidermis development; IEA:Ensembl.
DR   GO; GO:0006631; P:fatty acid metabolic process; TAS:ProtInc.
DR   GO; GO:0015908; P:fatty acid transport; TAS:UniProtKB.
DR   GO; GO:0007507; P:heart development; IEA:Ensembl.
DR   GO; GO:0006629; P:lipid metabolic process; TAS:ProtInc.
DR   GO; GO:0042157; P:lipoprotein metabolic process; IEA:Ensembl.
DR   GO; GO:0032099; P:negative regulation of appetite; ISS:UniProtKB.
DR   GO; GO:0045776; P:negative regulation of blood pressure; IEA:Ensembl.
DR   GO; GO:0010887; P:negative regulation of cholesterol storage; IDA:BHF-UCL.
DR   GO; GO:0045820; P:negative regulation of glycolytic process; IC:BHF-UCL.
DR   GO; GO:0050728; P:negative regulation of inflammatory response; IDA:BHF-UCL.
DR   GO; GO:1903038; P:negative regulation of leukocyte cell-cell adhesion; IDA:BHF-UCL.
DR   GO; GO:0010745; P:negative regulation of macrophage derived foam cell differentiation; IDA:BHF-UCL.
DR   GO; GO:1901215; P:negative regulation of neuron death; IEA:Ensembl.
DR   GO; GO:1902894; P:negative regulation of pri-miRNA transcription from RNA polymerase II promoter; IDA:BHF-UCL.
DR   GO; GO:0032091; P:negative regulation of protein binding; IEA:Ensembl.
DR   GO; GO:0010871; P:negative regulation of receptor biosynthetic process; IDA:BHF-UCL.
DR   GO; GO:0010891; P:negative regulation of sequestering of triglyceride; IDA:BHF-UCL.
DR   GO; GO:0000122; P:negative regulation of transcription from RNA polymerase II promoter; IDA:BHF-UCL.
DR   GO; GO:2000678; P:negative regulation of transcription regulatory region DNA binding; IEA:Ensembl.
DR   GO; GO:0032000; P:positive regulation of fatty acid beta-oxidation; TAS:UniProtKB.
DR   GO; GO:0046321; P:positive regulation of fatty acid oxidation; ISS:BHF-UCL.
DR   GO; GO:0045722; P:positive regulation of gluconeogenesis; IEA:Ensembl.
DR   GO; GO:0045944; P:positive regulation of transcription from RNA polymerase II promoter; IDA:BHF-UCL.
DR   GO; GO:0045893; P:positive regulation of transcription, DNA-templated; IDA:UniProtKB.
DR   GO; GO:0072366; P:regulation of cellular ketone metabolic process by positive regulation of transcription from RNA polymerase II promoter; IDA:BHF-UCL.
DR   GO; GO:0042752; P:regulation of circadian rhythm; ISS:UniProtKB.
DR   GO; GO:0072363; P:regulation of glycolytic process by positive regulation of transcription from RNA polymerase II promoter; IDA:BHF-UCL.
DR   GO; GO:0072369; P:regulation of lipid transport by positive regulation of transcription from RNA polymerase II promoter; IDA:BHF-UCL.
DR   GO; GO:0001666; P:response to hypoxia; IEA:Ensembl.
DR   GO; GO:0032868; P:response to insulin; IEA:Ensembl.
DR   GO; GO:0006367; P:transcription initiation from RNA polymerase II promoter; TAS:Reactome.
DR   GO; GO:0042060; P:wound healing; IEA:Ensembl.
DR   Gene3D; 3.30.50.10; -; 1.
DR   InterPro; IPR003074; 1Cnucl_rcpt.
DR   InterPro; IPR003076; 1Cnucl_rcpt_A.
DR   InterPro; IPR000536; Nucl_hrmn_rcpt_lig-bd.
DR   InterPro; IPR001723; Nuclear_hrmn_rcpt.
DR   InterPro; IPR001628; Znf_hrmn_rcpt.
DR   InterPro; IPR013088; Znf_NHR/GATA.
DR   Pfam; PF00104; Hormone_recep; 1.
DR   Pfam; PF00105; zf-C4; 1.
DR   PRINTS; PR01288; PROXISOMEPAR.
DR   PRINTS; PR01289; PROXISOMPAAR.
DR   PRINTS; PR00398; STRDHORMONER.
DR   PRINTS; PR00047; STROIDFINGER.
DR   SMART; SM00430; HOLI; 1.
DR   SMART; SM00399; ZnF_C4; 1.
DR   SUPFAM; SSF48508; SSF48508; 1.
DR   PROSITE; PS00031; NUCLEAR_REC_DBD_1; 1.
DR   PROSITE; PS51030; NUCLEAR_REC_DBD_2; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Activator; Alternative splicing; Biological rhythms;
KW   Complete proteome; DNA-binding; Lipid-binding; Metal-binding; Nucleus;
KW   Polymorphism; Receptor; Reference proteome; Transcription;
KW   Transcription regulation; Zinc; Zinc-finger.
FT   CHAIN         1    468       Peroxisome proliferator-activated
FT                                receptor alpha.
FT                                /FTId=PRO_0000053481.
FT   DNA_BIND     99    173       Nuclear receptor. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00407}.
FT   ZN_FING     102    122       NR C4-type. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00407}.
FT   ZN_FING     139    161       NR C4-type. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00407}.
FT   REGION      280    468       Ligand-binding.
FT   REGION      304    433       Required for heterodimerization with
FT                                RXRA.
FT   BINDING     280    280       Synthetic agonist.
FT                                {ECO:0000269|PubMed:11587644,
FT                                ECO:0000269|PubMed:11698662,
FT                                ECO:0000269|PubMed:11845213,
FT                                ECO:0000269|PubMed:17157019,
FT                                ECO:0000269|PubMed:17243659}.
FT   BINDING     314    314       Synthetic agonist.
FT                                {ECO:0000269|PubMed:11587644,
FT                                ECO:0000269|PubMed:11698662,
FT                                ECO:0000269|PubMed:11845213,
FT                                ECO:0000269|PubMed:17157019,
FT                                ECO:0000269|PubMed:17243659}.
FT   BINDING     440    440       Synthetic agonist.
FT                                {ECO:0000269|PubMed:11587644,
FT                                ECO:0000269|PubMed:11698662,
FT                                ECO:0000269|PubMed:11845213,
FT                                ECO:0000269|PubMed:17157019,
FT                                ECO:0000269|PubMed:17243659}.
FT   BINDING     464    464       Synthetic agonist.
FT                                {ECO:0000269|PubMed:11587644,
FT                                ECO:0000269|PubMed:11698662,
FT                                ECO:0000269|PubMed:11845213,
FT                                ECO:0000269|PubMed:17157019,
FT                                ECO:0000269|PubMed:17243659}.
FT   SITE        433    433       Essential for heterodimerization with
FT                                RXRA.
FT   VAR_SEQ     171    174       IRFG -> FCHT (in isoform 2).
FT                                {ECO:0000303|Ref.6}.
FT                                /FTId=VSP_047571.
FT   VAR_SEQ     175    468       Missing (in isoform 2).
FT                                {ECO:0000303|Ref.6}.
FT                                /FTId=VSP_047572.
FT   VARIANT     127    127       R -> Q (in dbSNP:rs1800204).
FT                                /FTId=VAR_016110.
FT   VARIANT     162    162       L -> V (in dbSNP:rs1800206).
FT                                {ECO:0000269|Ref.10}.
FT                                /FTId=VAR_016111.
FT   VARIANT     227    227       V -> A (in dbSNP:rs1800234).
FT                                /FTId=VAR_016112.
FT   VARIANT     268    268       A -> V (in dbSNP:rs1042311).
FT                                {ECO:0000269|PubMed:7684926}.
FT                                /FTId=VAR_016113.
FT   VARIANT     304    304       D -> N (in dbSNP:rs1800242).
FT                                /FTId=VAR_016114.
FT   VARIANT     395    395       G -> R (in dbSNP:rs2229245).
FT                                /FTId=VAR_050578.
FT   VARIANT     409    409       R -> T (in dbSNP:rs1800243).
FT                                /FTId=VAR_016115.
FT   MUTAGEN     122    122       C->G: Prevents DNA binding but no effect
FT                                on heterodimerization with RXRA.
FT                                {ECO:0000269|PubMed:7629123}.
FT   MUTAGEN     304    304       D->A: Reduced heterodimerization with
FT                                RXRA. Reduced DNA binding.
FT                                {ECO:0000269|PubMed:10195690}.
FT   MUTAGEN     370    370       L->R: Abolishes heterodimerization with
FT                                RXRA. No DNA binding.
FT                                {ECO:0000269|PubMed:10195690}.
FT   MUTAGEN     391    391       L->R: Abolishes heterodimerization with
FT                                RXRA. No DNA binding.
FT                                {ECO:0000269|PubMed:10195690}.
FT   MUTAGEN     422    422       L->R: No effect on heterodimerization
FT                                with RXRA nor on DNA binding and
FT                                transactivation activity.
FT                                {ECO:0000269|PubMed:7629123}.
FT   MUTAGEN     431    431       A->T: No effect on heterodimerization
FT                                with RXRA nor on DNA binding.
FT                                {ECO:0000269|PubMed:10195690}.
FT   MUTAGEN     433    433       L->R: Abolishes heterodimerization with
FT                                RXRA, DNA binding and transactivation
FT                                activity. {ECO:0000269|PubMed:7629123}.
FT   CONFLICT     71     71       T -> M (in Ref. 3; CAA68898).
FT                                {ECO:0000305}.
FT   CONFLICT    123    123       K -> M (in Ref. 3; CAA68898).
FT                                {ECO:0000305}.
FT   CONFLICT    296    296       G -> A (in Ref. 1; AAA36468).
FT                                {ECO:0000305}.
FT   CONFLICT    444    444       V -> A (in Ref. 3; CAA68898).
FT                                {ECO:0000305}.
FT   HELIX       203    217       {ECO:0000244|PDB:3VI8}.
FT   HELIX       222    229       {ECO:0000244|PDB:3VI8}.
FT   STRAND      233    235       {ECO:0000244|PDB:1K7L}.
FT   STRAND      239    241       {ECO:0000244|PDB:3VI8}.
FT   HELIX       244    254       {ECO:0000244|PDB:3VI8}.
FT   HELIX       256    259       {ECO:0000244|PDB:3VI8}.
FT   HELIX       263    265       {ECO:0000244|PDB:2P54}.
FT   HELIX       268    290       {ECO:0000244|PDB:3VI8}.
FT   HELIX       291    293       {ECO:0000244|PDB:3VI8}.
FT   TURN        295    299       {ECO:0000244|PDB:3VI8}.
FT   HELIX       302    321       {ECO:0000244|PDB:3VI8}.
FT   HELIX       322    324       {ECO:0000244|PDB:3VI8}.
FT   STRAND      329    332       {ECO:0000244|PDB:3VI8}.
FT   TURN        333    336       {ECO:0000244|PDB:3VI8}.
FT   STRAND      337    340       {ECO:0000244|PDB:3VI8}.
FT   HELIX       341    346       {ECO:0000244|PDB:3VI8}.
FT   TURN        349    351       {ECO:0000244|PDB:3VI8}.
FT   HELIX       352    366       {ECO:0000244|PDB:3VI8}.
FT   HELIX       372    383       {ECO:0000244|PDB:3VI8}.
FT   HELIX       394    415       {ECO:0000244|PDB:3VI8}.
FT   HELIX       422    450       {ECO:0000244|PDB:3VI8}.
FT   STRAND      453    456       {ECO:0000244|PDB:1KKQ}.
FT   HELIX       458    464       {ECO:0000244|PDB:3VI8}.
FT   TURN        465    467       {ECO:0000244|PDB:2ZNN}.
SQ   SEQUENCE   468 AA;  52225 MW;  850846FD51ADA883 CRC64;
     MVDTESPLCP LSPLEAGDLE SPLSEEFLQE MGNIQEISQS IGEDSSGSFG FTEYQYLGSC
     PGSDGSVITD TLSPASSPSS VTYPVVPGSV DESPSGALNI ECRICGDKAS GYHYGVHACE
     GCKGFFRRTI RLKLVYDKCD RSCKIQKKNR NKCQYCRFHK CLSVGMSHNA IRFGRMPRSE
     KAKLKAEILT CEHDIEDSET ADLKSLAKRI YEAYLKNFNM NKVKARVILS GKASNNPPFV
     IHDMETLCMA EKTLVAKLVA NGIQNKEAEV RIFHCCQCTS VETVTELTEF AKAIPGFANL
     DLNDQVTLLK YGVYEAIFAM LSSVMNKDGM LVAYGNGFIT REFLKSLRKP FCDIMEPKFD
     FAMKFNALEL DDSDISLFVA AIICCGDRPG LLNVGHIEKM QEGIVHVLRL HLQSNHPDDI
     FLFPKLLQKM ADLRQLVTEH AQLVQIIKKT ESDAALHPLL QEIYRDMY
//
